Comparison of Estimated SARS-CoV-2 Seroprevalence through Commercial Laboratory Residual Sera Testing and a Community Survey

Details

• Alternative Title:
  Clin Infect Dis
• Personal Author:
  Bajema, Kristina L ; Dahlgren, F Scott ; Lim, Travis W ; Bestul, Nicolette ; Biggs, Holly M ; Tate, Jacqueline E ; Owusu, Claudio ; Szablewski, Christine M ; Drenzek, Cherie ; Drobeniuc, Jan ; Semenova, Vera ; Li, Han ; Browning, Peter ; Desai, Rita ; Epperson, Monica ; Jia, Lily T ; Thornburg, Natalie J ; Edens, Chris ; Fry, Alicia M ; Hall, Aron J ; Schiffer, Jarad ; Havers, Fiona P
• Description:
  We compared severe acute respiratory syndrome-related coronavirus-2 seroprevalence estimated from commercial laboratory residual sera and a community household survey in metropolitan Atlanta during April-May 2020 and found these two estimates to be similar (4.94% versus 3.18%). Compared with more representative surveys, commercial sera can provide an approximate measure of seroprevalence.
• Subjects:
  Coronavirus Infections COVID-19
• Source:
  Clin Infect Dis. 2020;
• Pubmed ID:
  33300579
• Pubmed Central ID:
  PMC7799302
• Document Type:
  Journal Article
• Collection(s):
  CDC Public Access
• Main Document Checksum:
  urn:sha256:1859ed0c160d990e955dafc7681de1fc761aa86076d49bdf098f48b485de9a61
• Download URL:
  https://stacks.cdc.gov/view/cdc/102940/cdc_102940_DS1.pdf
• File Type:
  [PDF - 315.09 KB ]